RR-TZ — 500mcg | Research Use Only (RUO)

Description

A synthetic peptide compound currently investigated in controlled laboratory environments for its dual activity at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and related incretin-signaling pathways.

For laboratory research use only. Not for human or animal consumption.

OVERVIEW

Tirzepatide is a synthetic 39-amino-acid peptide studied for its dual agonist activity at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). Laboratory and preclinical research has examined its effects on incretin-receptor signaling, glucose-dependent cellular signaling, metabolic regulation, and downstream pathways associated with energy homeostasis.

Structurally, tirzepatide is based in part on the endogenous GIP peptide sequence and incorporates a C20 fatty-diacid moiety designed to influence albumin binding and molecular stability.

Supplied in capsule form for analytical, formulation, and controlled experimental research applications.

PRODUCT SPECIFICATIONS

Compound: Tirzepatide
Quantity: 500 mcg per capsule
Capsule Count: 30 capsules
Form: Capsule
Compound Class: Synthetic peptide / dual GIPR and GLP-1R agonist
Purity: See batch-specific Certificate of Analysis
Storage: Store under cool, dry conditions protected from excessive heat, moisture, and direct light. Follow batch-specific handling instructions where provided.

RESEARCH APPLICATIONS

• GIP receptor signaling studies
• GLP-1 receptor signaling studies
• Dual incretin-receptor activation research
• Receptor-mediated cellular signaling analysis
• Metabolic signaling pathway research
• Glucose-dependent signaling models
• Peptide-receptor interaction studies
• Experimental formulation and stability research

RESEARCH BACKGROUND

Tirzepatide has been characterized as a dual GIPR/GLP-1R agonist capable of activating both incretin-receptor pathways. Research has examined how simultaneous activity at these receptors influences intracellular signaling and metabolic regulatory mechanisms.

The molecule consists of a 39-amino-acid peptide sequence conjugated to a C20 fatty-diacid moiety through a linker. This structural modification contributes to albumin binding and has made tirzepatide an important research compound for studying prolonged peptide-receptor activity and dual incretin signaling.

Its combined receptor profile has also made tirzepatide useful in experimental models investigating the individual and combined contributions of GIPR and GLP-1R signaling.

RESEARCH USE ONLY

This product is intended strictly for laboratory research purposes. Not for human consumption. Not for veterinary use. Not for therapeutic or diagnostic applications. Not intended to treat, cure, or prevent any condition.

The capsule format is provided solely as a research formulation and should not be interpreted as an approved oral pharmaceutical preparation.

Use is limited to qualified professionals in controlled laboratory environments.

Certificate of Analysis available upon request.